Chitosan-Coated Lipid-Core Nanocapsules Functionalized with Gold-III and Bevacizumab Induced In Vitro Cytotoxicity against C6 Cell Line and In Vivo Potent Antiangiogenic Activity

Alves, Aline de Cristo Soares; Lavayen, Vladimir; Figueiró, Fabrício; Dallemole, Danieli Rosane; Dias, Amanda de Fraga; Cé, Rodrigo; Battastini, Ana Maria Oliveira; Guterres, Sílvia Stanisçuaski; Pohlmann, Adriana Raffin

doi:10.1007/s11095-020-02804-0

Cited by 13 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies can be conjugated on the surface of nanocarriers to improve the specificity of delivery to target tissues or specific cell antigens [ 32 , 106 ]. In a recent study, we decorated the surface of chitosan-coated lipid-core nanocapsules with BCZ by forming an organometallic complex with gold-III ( d = 183 nm; ζ potential = +18.5 mV) [ 66 ]. Another study reported the development of BCZ-coated PLA nanoparticles ( d = 265 nm) inserted into porous PLGA microparticles (11.61 µm) [ 67 ].…”

Section: Development Of Nanoparticulate Drug Delivery Systems For Bczmentioning

confidence: 99%

“…In a recent report, we demonstrated that BCZ-functionalized-chitosan-coated lipid-core nanocapsules (BCZ-MLNC) tested against rat glioma (C6) showed decreased cell viability with a IC50 of 30 nmol L −1 . Furthermore, BCZ-MLNC showed concentration and time-dependent cellular internalization [ 66 ].…”

Section: Pharmacological Applicationsmentioning

confidence: 99%

“…In CAM model, BCZ-MLNC caused a higher antiangiogenic effect than BCZ in solution. Dosage decreases of 5.6 times and 2.9 times, respectively in the absence and presence of VEGF, were observed compared to BCZ solution [ 66 ]. Using a glioblastoma model in mice, BCZ-loaded PLGA nanoparticles reduced more the tumor growth than the control group with a decrease in the VEGF mRNA expression.…”

Section: Pharmacological Applicationsmentioning

confidence: 99%

“…BCZ-loaded PCL core-shell nanofibers [ 60 ] or BCZ nanoparticles [ 62 ] produced at the isoelectric point of BCZ remained intact the antibody structure. The antiangiogenic activity was maintained after encapsulation or surface conjugation of BCZ analyzed in vitro against cells lines [ 39 , 41 , 45 , 47 , 62 ] or in CAM model [ 55 , 61 , 66 , 68 ]. In animal models, BCZ encapsulated or surface conjugate demonstrated efficacy in the treatment of corneal neovascularization [ 45 , 58 ], choroidal neovascularization [ 68 ], antiangiogenic in a model of diabetes [ 54 ], non-small cell lung cancer [ 65 ], glioblastoma [ 48 ], melanoma [ 74 ], pancreatic adenocarcinoma combined with photodynamic therapy [ 40 ] and colorectal cancer [ 59 ].…”

Section: Limitations and Advantages Of Bcz Nanocarriersmentioning

confidence: 99%

See 3 more Smart Citations

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

et al. 2021

Self Cite

View full text Add to dashboard Cite

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

show abstract

Section: Development Of Nanoparticulate Drug Delivery Systems For Bczmentioning

confidence: 99%

Section: Pharmacological Applicationsmentioning

confidence: 99%

Section: Pharmacological Applicationsmentioning

confidence: 99%

Section: Limitations and Advantages Of Bcz Nanocarriersmentioning

confidence: 99%

See 2 more Smart Citations

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In recent years, drug delivery systems (DDSs) based on nanocarriers have been widely developed, and antitumor drug carriers (such as liposomes (Wang et al, 2020 ), micelles (Guan et al, 2020 ), polymer nanogels (Maiti et al, 2018 ), magnetic nanoparticles (NPs) (Avval et al, 2020 ), and nanocapsules (de Cristo Soares Alves et al, 2020 )) are usually produced on the nanoscale to increase their permeability and retention in tumor tissues. However, these carriers are identified as ‘nonself’ and are still quickly cleared by the immune system with a short half-life.…”

Section: Introductionmentioning

confidence: 99%

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Zhao

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Nanotechnology provides synthetic carriers for cancer drug delivery that protect cargos from degradation, control drug release and increase local accumulation at tumors. However, these non-natural vehicles display poor tumor targeting and potential toxicity and are eliminated by the immune system. Recently, biomimetic nanocarriers have been widely developed based on the concept of 'mimicking nature.' Among them, cell-derived biomimetic vehicles have become the focus of bionics research because of their multiple natural functions, such as low immunogenicity, long circulation time and targeting ability. Cell membrane-coated carriers and extracellular vesicles are two widely used cell-based biomimetic materials. Here, this review summarizes the latest progress in the application of these two biomimetic carriers in targeted cancer therapy. Their properties and performance are compared, and their future challenges and development prospects are discussed.

show abstract

Combined cancer therapeutics—Tackling the complexity of the tumor microenvironment

Roma‐Rodrigues

Raposo

Valente

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Cancer treatment has yet to find a “silver bullet” capable of selectively and effectively kill tumor cells without damaging healthy cells. Nanomedicine is a promising field that can combine several moieties in one system to produce a multifaceted nanoplatform. The tumor microenvironment (TME) is considered responsible for the ineffectiveness of cancer therapeutics and the difficulty in the translation from the bench to bed side of novel nanomedicines. A promising approach is the use of combinatorial therapies targeting the TME with the use of stimuli‐responsive nanomaterials which would increase tumor targeting. Contemporary combined strategies for TME‐targeting nanoformulations are based on the application of external stimuli therapies, such as photothermy, hyperthermia or ultrasounds, in combination with stimuli‐responsive nanoparticles containing a core, usually composed by metal oxides or graphene, and a biocompatible stimuli‐responsive coating layer that could also contain tumor targeting moieties and a chemotherapeutic agent to enhance the therapeutic efficacy. The obstacles that nanotherapeutics must overcome in the TME to accomplish an effective therapeutic cargo delivery and the proposed strategies for improved nanotherapeutics will be reviewed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Chitosan-Coated Lipid-Core Nanocapsules Functionalized with Gold-III and Bevacizumab Induced In Vitro Cytotoxicity against C6 Cell Line and In Vivo Potent Antiangiogenic Activity

Cited by 13 publications

References 55 publications

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Combined cancer therapeutics—Tackling the complexity of the tumor microenvironment

Contact Info

Product

Resources

About